Sponsor · clinical trials

Merck Sharp & Dohme clinical trials

Source: ClinicalTrials.gov, U.S. National Library of Medicine and the EU Clinical Trials Information System (CTIS) — current trials in our USA, Spain, South Korea, Italy, UK, Canada, Israel, France, Australia, Poland, Japan, Germany, Turkey, China, Taiwan, Brazil, Netherlands, Mexico, Belgium, Denmark, Czechia, Switzerland, Sweden, Ireland, Singapore, Norway, Portugal, Austria, India, Egypt and EU (CTIS) registers with Merck Sharp & Dohme as lead sponsor. Synced 10 Nov 2026

220Current trials

117Recruiting now

168Drugs in these trials

31Trial registers

Maintained by Sreepriya Prasannan

MSc Digital Transformation of Life Sciences (Innopharma Education / Griffith College); MSc & BSc Botany HSE Spark Ignite 2026 — Top 14 finalist

Compiled from ClinicalTrials.gov and CTIS registry records · Synced 10 Nov 2026 · Editorial standards

At a glance

Merck Sharp & Dohme is the lead sponsor of 220 current clinical trials in our USA, Spain, South Korea, Italy, UK, Canada, Israel, France, Australia, Poland, Japan, Germany, Turkey, China, Taiwan, Brazil, Netherlands, Mexico, Belgium, Denmark, Czechia, Switzerland, Sweden, Ireland, Singapore, Norway, Portugal, Austria, India, Egypt and EU (CTIS) registers. 117 are recruiting patients now. The most common phase is Phase 3. The drugs named most often in its trials are Pembrolizumab, Keytruda and Paclitaxel. The most-studied condition is Healthy.

Company profiles on this site (news, sites, medicines, approvals): Merck & Co. (US) →MSD Ireland (IE) →

ClinicalTrials.gov trials by status

Recruiting11756%
Not yet open10%
Active, closed9244%

Trials by phase

Phase 39646%
Phase 24923%
Phase 1/23115%
Phase 12512%
Phase 2/373%
Observational10%
Phase 410%

Clinical trials sponsored by Merck Sharp & Dohme

210 on ClinicalTrials.gov

Study	Phase	Status	Start	Registers
Long-term Safety and Efficacy Extension Study for Participants With Advanced Tumors Who Are Currently on Treatment or in Follow-up in a Pembrolizumab (MK-3475) Study (MK-3475-587/KEYNOTE-587) NCT03486873 · Solid Tumors, Hematologic Malignancies Drugs: ) Berahyaluronidase alfa, Keytruda, Lenvatinib	Phase 3	Recruiting	2018-08	Ireland, UK, USA, China, Germany, France, Spain, Italy, Netherlands, Belgium, Sweden, Denmark, Poland, Switzerland, Austria, Czechia, Norway, Portugal, Turkey, Canada, Brazil, Mexico, Japan, South Korea, Taiwan, Singapore, Australia, Israel
A Clinical Study of MK-3120 in People With Bladder Cancer (MK-3120-003) NCT07222488 · Bladder Cancer, Urinary Bladder Neoplasms Drug: MK-3120	Phase 1/2	Recruiting	2025-12	USA, France, Spain, Italy, Netherlands, Belgium, Austria, Norway, Turkey, Canada, Israel
A Study of Opevesostat (MK-5684) Versus Alternative Next-generation Hormonal Agent (NHA) in Metastatic Castration-resistant Prostate Cancer (mCRPC) Post One NHA (MK-5684-004) NCT06136650 · Metastatic Castration-resistant Prostate Cancer (mCRPC), Prostatic Neoplasms Drugs: Abiraterone acetate, Dexamethasone, Enzalutamide	Phase 3	Recruiting	2023-12	Ireland, UK, USA, China, Germany, France, Spain, Italy, Sweden, Czechia, Portugal, Turkey, Canada, Brazil, Mexico, Japan, South Korea, Taiwan, Singapore, Australia, Israel
A Clinical Trial of Sacituzumab Tirumotecan (Sac-TMT, MK-2870) to Treat Urothelial Cancer (MK-2870-031) NCT07419295 · Bladder Cancer Drugs: Docetaxel, Paclitaxel, Sacituzumab tirumotecan	Phase 3	Recruiting	2026-04	UK, USA, China, Germany, France, Spain, Italy, Netherlands, Belgium, Sweden, Canada, Brazil, Japan, Australia, Israel
A Study of MK-5684 in People With Certain Solid Tumors (MK-5684-015/OMAHA-015) NCT06979596 · Malignant Neoplasm Drugs: Exemestane, Fulvestrant, Letrozole	Phase 2	Recruiting	2025-08	UK, USA, Spain, Turkey, Canada, Brazil, Taiwan, Singapore
A Clinical Study of MK-8294 in Participants With Advanced Solid Tumors (MK-8294-001) NCT07030712 · Metastatic Neoplasm	Phase 1	Recruiting	2025-07	USA, Netherlands, Israel
A Study to Evaluate the Safety and Efficacy of MK-3120 in Participants With Advanced Solid Tumors (MK-3120-002) NCT06818643 · Advanced Solid Tumors, Malignant Neoplasm Drug: MK-3120	Phase 1/2	Recruiting	2025-03	USA, China, France, Spain, Netherlands, Poland, Turkey, Japan, South Korea, Taiwan, Israel
A Clinical Study of Belzutifan and Zanzalintinib in People With Recurrent Kidney Cancer Following Adjuvant Therapy (MK-6482-033) NCT07227402 · Renal Cell Carcinoma Drugs: Belzutifan, Cabozantinib, Zanzalintinib	Phase 3	Recruiting	2025-11	Ireland, UK, USA, China, Germany, France, Spain, Italy, Belgium, Denmark, Poland, Austria, Czechia, Brazil, Mexico, South Korea, Taiwan, Singapore, Australia
A Study to Evaluate the Efficacy and Safety of Sacituzumab Tirumotecan (MK-2870) Maintenance Treatment Versus Standard of Care in Participants With Platinum-sensitive Recurrent Ovarian Cancer (MK-2870-022/TroFuse-022/ENGOT-ov84/GOG-3103) NCT06824467 · Ovarian Cancer, Fallopian Tube Cancer, Primary Peritoneal Cancer Drugs: Acetaminophen, Avastin, Bevacizumab	Phase 3	Recruiting	2025-04	Ireland, UK, USA, France, Spain, Italy, Belgium, Denmark, Poland, Austria, Czechia, Portugal, Canada, Brazil, Mexico, Japan, South Korea, Taiwan, Australia, Israel
Sacituzumab Tirumotecan (MK-2870) Plus Pembrolizumab Versus TPC in TNBC Who Did Not Achieve pCR (MK-2870-012) NCT06393374 · Triple-Negative Breast Cancer Drugs: Capecitabine, Keytruda, Pembrolizumab	Phase 3	Recruiting	2024-06	Ireland, UK, USA, Germany, France, Spain, Italy, Belgium, Sweden, Denmark, Poland, Switzerland, Austria, Czechia, Norway, Portugal, Turkey, Canada, Brazil, Mexico, Japan, South Korea, Singapore, Australia, Israel
A Clinical Study of Zilovertamab Vedotin (MK-2140) Plus Rituximab Plus Cyclophosphamide, Doxorubicin, and Prednisone (R-CHP) Versus Polatuzumab Vedotin Plus R-CHP in People With Diffuse Large B-cell Lymphoma (DLBCL) (MK-2140-011/waveLINE-011) NCT06890884 · Lymphoma, Large B-Cell, Diffuse Drugs: Adriamycin, Cyclophosphamide, Cytoxan	Phase 2	Recruiting	2025-04	Ireland, UK, USA, Germany, Italy, Belgium, Poland, Japan, Israel, Egypt
A Study of Sacituzumab Tirumotecan (MK-2870) as a Single Agent and in Combination With Pembrolizumab (MK-3475) Versus Treatment of Physician's Choice in Participants With HR+/HER2- Unresectable Locally Advanced or Metastatic Breast Cancer (MK-2870-010) NCT06312176 · Breast Neoplasms Drugs: Abraxane, Capecitabine, Keytruda	Phase 3	Recruiting	2024-04	Ireland, UK, USA, India, Germany, France, Spain, Italy, Netherlands, Belgium, Sweden, Denmark, Poland, Switzerland, Czechia, Portugal, Turkey, Canada, Brazil, Mexico, Japan, South Korea, Taiwan, Singapore, Australia, Israel
A Study to Evaluate Efficacy and Safety of MK-8690 in Participants With Moderately to Severely Active Ulcerative Colitis (MK-8690-002) NCT07463183 · Colitis Ulcerative, Ulcerative Colitis	Phase 2	Recruiting	2026-03	UK, USA, Germany, France, Italy, Netherlands, Poland, Canada, South Korea
A Study of Nemtabrutinib Plus Venetoclax vs Venetoclax + Rituximab (VR) in Second-line (2L) + Relapsed/Refractory (R/R) Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma (CLL/SLL) (MK-1026-010/BELLWAVE-010). NCT05947851 · Leukemia, Lymphocytic, Chronic, B-Cell, Leukemia, Chronic Lymphocytic, Small-Cell Lymphoma Drugs: Nemtabrutinib, Rituximab, Venetoclax	Phase 3	Recruiting	2023-08	UK, USA, Germany, France, Spain, Italy, Belgium, Portugal, Turkey, Canada, Brazil, Mexico, Japan, Taiwan, Australia, Israel
A Study of Sotatercept (MK-7962) in People With Pulmonary Arterial Hypertension (PAH) in India (MK-7962-037) NCT07600723 · ClinicalTrials.gov ↗ · Pulmonary Arterial Hypertension Drug: Sotatercept	Phase 4	Recruiting	2026-10	India
Efficacy, Safety, and Pharmacokinetics of Vericiguat in Pediatric Participants With Heart Failure Due to Left Ventricular Systolic Dysfunction (MK-1242-036) NCT05714085 · Heart Failure, Left Ventricular Systolic Dysfunction Drug: Vericiguat	Phase 2/3	Recruiting	2023-05	Ireland, UK, USA, Germany, France, Spain, Italy, Netherlands, Belgium, Sweden, Denmark, Poland, Portugal, Turkey, Canada, Brazil, Mexico, South Korea, Singapore
A Study to Compare Sacituzumab Tirumotecan (MK-2870) in Combination With Pembrolizumab (MK-3475) Versus Pembrolizumab Alone as Treatment in Participants With Mismatch Repair Proficient Endometrial Cancer (MK-2870-033/TroFuse-033/GOG-3119/ENGOT-en29) NCT06952504 · Endometrial Cancer Drugs: Carboplatin, Cisplatin, Docetaxel	Phase 3	Recruiting	2025-05	Ireland, UK, USA, China, Germany, France, Spain, Italy, Netherlands, Belgium, Sweden, Denmark, Poland, Austria, Czechia, Norway, Canada, Brazil, Mexico, Japan, South Korea, Taiwan, Singapore, Australia, Israel
Study of Patritumab Deruxtecan With Other Anticancer Agents in Participants With HER2 Positive Breast Cancer That Has Spread and Cannot Be Surgically Removed (MK-1022-009) NCT06686394 · Breast Neoplasms, Breast Cancer Drugs: Herceptin, Herzuma, Ogivri	Phase 1/2	Recruiting	2025-02	UK, USA, Canada, Japan, South Korea, Israel
A Clinical Trial of MK-2010 With Sacituzumab Tirumotecan (Sac-TMT) in Participants With Solid Tumors (MK-2010) NCT07785609 · ClinicalTrials.gov ↗ · Advanced Solid Tumors, Malignant Neoplasm Drugs: Acetaminophen, Dexamethasone, Epinephrine	Phase 2	Recruiting	2026-10	USA, Switzerland
A Clinical Trial of MK-7262 and Enlicitide in Participants With High Lipoprotein(a) (MK-7262-004) NCT07614984 · ClinicalTrials.gov ↗ · Lipoprotein(a) Drugs: Enlicitide, Enlicitide Decanoate, HRS-5346	Phase 2	Recruiting	2026-06	USA, Germany, Spain, Netherlands, Denmark, Switzerland, Canada, Mexico, Japan
A Study of Intismeran Autogene (V940)/Placebo + Pembrolizumab and Chemotherapy in Metastatic Squamous Non-Small Cell Lung Cancer (V940-013) NCT07221474 · Squamous Non-small Cell Lung Cancer Drugs: Carboplatin, Intismeran autogene, Keytruda	Phase 2	Recruiting	2025-12	USA, China, France, Spain, Italy, Poland, Turkey, South Korea, Taiwan, Australia
A Clinical Study of Ifinatamab Deruxtecan (I-DXd) in People With Metastatic Prostate Cancer (MK-2400-001) NCT06925737 · Prostate Cancer, Prostatic Neoplasms Drugs: Docetaxel, Ifinatamab Deruxtecan, Prednisolone	Phase 3	Recruiting	2025-05	Ireland, UK, USA, China, Germany, France, Spain, Italy, Netherlands, Sweden, Denmark, Poland, Switzerland, Austria, Czechia, Norway, Turkey, Brazil, Mexico, Japan, South Korea, Taiwan, Singapore, Australia, Israel
A Clinical Study of MK-2870 Alone or With Other Treatments to Treat Gastrointestinal Cancers (MK-9999-02A) NCT06428409 · Colorectal Cancer, Pancreatic Ductal Adenocarcinoma, Biliary Tract Cancer Drugs: Adrucil, Cisplatin, Fluorouracil	Phase 1/2	Recruiting	2024-06	UK, USA, China, Spain, Italy, Switzerland, Turkey, Canada, Japan, South Korea, Taiwan, Australia
A Clinical Study of Gocatamig (MK-6070) and Infinatamab Deruxtecan (MK-2400) in People With Small Cell Lung Cancer (MK-6070-003) NCT07227597 · Small Cell Lung Cancer Extensive Stage Drugs: Atezolizumab, Carboplatin, Etoposide	Phase 1/2	Recruiting	2026-01	USA, China, Germany, Spain, Italy, Poland, Turkey, South Korea, Israel
Pembrolizumab With or Without Maintenance Sacituzumab Tirumotecan (Sac-TMT; MK-2870) in Metastatic Squamous Non-small Cell Lung Cancer (NSCLC) [MK-2870-023] NCT06422143 · Non-small Cell Lung Cancer, NSCLC Drugs: Carboplatin, Keytruda, Nab-paclitaxel	Phase 3	Recruiting	2024-06	Ireland, UK, USA, China, Germany, France, Spain, Italy, Poland, Austria, Czechia, Turkey, Canada, Brazil, Mexico, Japan, South Korea, Taiwan, Israel
A Clinical Study of MK-2214 in People With Early Alzheimer's Disease (MK-2214-004) NCT07033494 · Early Alzheimer's Disease	Phase 2	Recruiting	2025-07	UK, USA, Spain, Netherlands, Belgium, Canada, Japan, South Korea, Singapore, Australia
A Clinical Study of Novel Pneumococcal Vaccine V118C in Children (V118C-002) NCT07300267 · Pneumococcal Infection Drug: PCV20	Phase 1	Recruiting	2026-01	USA
A Study to Evaluate the Efficacy and Safety of Tulisokibart (MK-7240) in Participants With Moderate to Severe Crohn's Disease (MK-7240-008) NCT06430801 · Crohn's Disease Drug: Tulisokibart	Phase 3	Recruiting	2024-06	Ireland, UK, USA, China, Germany, France, Spain, Italy, Netherlands, Belgium, Sweden, Denmark, Poland, Switzerland, Austria, Czechia, Portugal, Turkey, Canada, Brazil, Mexico, Japan, South Korea, Taiwan, Singapore, Australia, Israel
Study to Evaluate Sotatercept (MK-7962) in Children With Pulmonary Arterial Hypertension (PAH) (MK-7962-008) NCT05587712 · Pulmonary Arterial Hypertension Drug: Sotatercept	Phase 2	Recruiting	2023-01	UK, USA, Germany, France, Spain, Netherlands, Poland, Turkey, Australia, Israel
Extension Study of Long-term Safety and Efficacy of Tulisokibart in Participants With Crohn's Disease or Ulcerative Colitis (MK-7240-011) NCT06651281 · Crohn Disease, Colitis, Ulcerative Drug: Tulisokibart	Phase 3	Recruiting	2024-11	UK, USA, France, Poland, Czechia
A Study of Enlicitide Decanoate (MK-0616, an Oral PCSK9 Inhibitor) in Children and Adolescents With Heterozygous Familial Hypercholesterolemia (MK-0616-029) NCT07058077 · Heterozygous Familial Hypercholesterolemia (HeFH) Drugs: Enlicitide, Enlicitide Decanoate	Phase 2/3	Recruiting	2025-08	UK, USA, China, Germany, France, Spain, Netherlands, Belgium, Poland, Czechia, Norway, Brazil, Mexico, Singapore, Australia
A Study to Evaluate Investigational Agents With or Without Pembrolizumab (MK-3475) in Participants With Advanced Esophageal Cancer Previously Exposed to Programmed Cell Death 1 Protein (PD-1)/ Programmed Cell Death Ligand 1 (PD-L1) Treatment (MK-3475-06B) NCT05319730 · Esophageal Squamous Cell Carcinoma Drugs: Acetaminophen, Dexamethasone, Irinotecan	Phase 1/2	Recruiting	2023-05	USA, China, Germany, Italy, Switzerland, Norway, Turkey, Brazil, Japan, South Korea, Taiwan, Singapore
Efficacy and Safety of Nemtabrutinib (MK-1026) in Participants With Hematologic Malignancies (MK-1026-003) NCT04728893 · Hematologic Malignancies, Waldenstroms Macroglobulinaemia, Non-Hodgkins Lymphoma Drug: Nemtabrutinib	Phase 2	Recruiting	2021-04	Ireland, UK, USA, China, Germany, France, Spain, Italy, Denmark, Poland, Switzerland, Czechia, Turkey, Canada, Brazil, South Korea, Australia, Israel
A Clinical Study of MK-4716 in People With Certain Solid Tumors (MK-4716-001) NCT07247110 · Malignant Neoplasm Drugs: Cetuximab, Keytruda, Pembrolizumab	Phase 1	Recruiting	2025-12	USA, Spain, Canada, South Korea, Australia, Israel
Clinical Study of MK-4884 in Participants With Advanced or Metastatic Solid Tumors (MK-4884-001) NCT07600749 · Malignant Neoplasm	Phase 1	Recruiting	2026-06	USA, Switzerland, Canada, Japan, Israel
A Clinical Study of Calderasib (MK-1084) and Other Treatments for Participants With Non-Small Cell Lung Cancer (MK-1084-007/KANDLELIT-007) NCT07190248 · Non-small Cell Lung Cancer Drugs: ) Berahyaluronidase alfa, Calderasib, Carboplatin	Phase 3	Recruiting	2025-10	UK, USA, China, France, Spain, Italy, Netherlands, Belgium, Poland, Switzerland, Austria, Turkey, Canada, Brazil, Mexico, Japan, South Korea, Taiwan, Australia, Israel
A Study of Pembrolizumab (MK-3475) With or Without Intismeran Autogene (V940) in Participants With Non-small Cell Lung Cancer (V940-009/INTerpath-009) NCT06623422 · Carcinoma, Non-Small-Cell Lung Drugs: Carboplatin, Cisplatin, Gemcitabine	Phase 3	Recruiting	2024-10	Ireland, UK, USA, China, Germany, France, Spain, Italy, Netherlands, Belgium, Sweden, Poland, Turkey, Canada, Brazil, Japan, South Korea, Taiwan, Singapore, Australia, Israel
Study of Opevesostat (MK-5684) Versus Alternative NHA in mCRPC (MK-5684-003) NCT06136624 · Prostate Cancer Metastatic Drugs: Abiraterone acetate, Dexamethasone, Enzalutamide	Phase 3	Recruiting	2023-12	Ireland, UK, USA, China, Germany, France, Spain, Italy, Netherlands, Sweden, Denmark, Poland, Austria, Czechia, Norway, Turkey, Canada, Brazil, Mexico, Japan, South Korea, Taiwan, Singapore, Australia, Israel
A Study to Evaluate the Safety and Efficacy of Gocatamig (MK-6070) and Ifinatamab Deruxtecan (I-DXd) in Participants With Relapsed/Refractory Extensive-Stage Small Cell Lung Cancer (MK-6070-002) NCT06780137 · Small Cell Lung Cancer Drugs: Durvalumab, Gocatamig, Ifinatamab Deruxtecan	Phase 1/2	Recruiting	2025-02	UK, USA, China, Spain, Turkey, Japan, South Korea, Taiwan, Australia, Israel
Ensifentrine (MK-5884) Study for the Prevention of Chronic Obstructive Pulmonary Disease (COPD) Exacerbations in Adults With a History of Moderate or Severe Exacerbations While Receiving Standard of Care (SOC) (MK-5884-031/RPL554/ENHANCE-3) NCT07874815 · ClinicalTrials.gov ↗ · Pulmonary Disease, Chronic Obstructive Drug: Ensifentrine	Phase 3	Recruiting	2026-11	USA
A Clinical Study of MK-1045 in People With Lupus or Rheumatoid Arthritis (MK-1045-004) NCT07363590 · Systemic Lupus Erythematosus, Rheumatoid Arthritis Drug: MK-1045	Phase 1	Recruiting	2026-02	China, Italy, Belgium, Japan, Australia
A Clinical Trial of Sac-TMT in People With Non-HRD Positive Advanced Ovarian Cancer (MK-2870-021) NCT07318558 · Ovarian Neoplasms, Ovarian Cancer Drugs: Avastin, Bevacizumab, Mvasi	Phase 3	Recruiting	2026-02	Ireland, UK, USA, Germany, France, Spain, Italy, Belgium, Sweden, Denmark, Poland, Switzerland, Austria, Czechia, Norway, Canada, Brazil, Japan, South Korea, Taiwan, Australia, Israel
A Clinical Study of Sacituzumab Tirumotecan (MK-2870) in Combination With Pembrolizumab (MK-3475) as First-line Maintenance Treatment of Cervical Cancer (MK-2870-036/TroFuse-036/GOG-3123/ENGOT-cx22) NCT07216703 · Cervical Cancer Drugs: Avastin, Bevacizumab, Carboplatin	Phase 3	Recruiting	2026-01	Ireland, UK, USA, India, Germany, France, Spain, Italy, Belgium, Sweden, Denmark, Poland, Austria, Czechia, Canada, Brazil, Mexico, Japan, South Korea, Taiwan, Israel
Substudy 06E: Umbrella Study of Combination Therapies in Esophageal Cancer (MK-3475-06E/KEYMAKER-U06) NCT06780111 · Esophageal Squamous Cell Carcinoma Drugs: Adrucil, Ifinatamab Deruxtecan, Keytruda	Phase 1/2	Recruiting	2025-07	USA, China, Germany, France, Italy, Switzerland, Czechia, Norway, Turkey, Brazil, Japan, South Korea, Taiwan, Singapore
A Clinical Trial of Sacituzumab Tirumotecan (Sac-TMT, MK-2870) and Pembrolizumab (MK-3475A) in Participants With Bladder Cancer (MK-2870-055) NCT07829783 · ClinicalTrials.gov ↗ · Bladder Cancer Drugs: Adrucil, Capecitabine, Cisplatin	Phase 3	Recruiting	2026-10	Taiwan
A Study of Calderasib (MK-1084) Plus Pembrolizumab (MK-3475) in Participants With KRAS G12C Mutant Non-small Cell Lung Cancer (NSCLC) With Programmed Cell Death Ligand 1 (PD-L1) Tumor Proportion Score (TPS) ≥50% (MK-1084-004/KANDLELIT-004) NCT06345729 · Non-small Cell Lung Cancer Drugs: Calderasib, Keytruda, Pembrolizumab	Phase 3	Recruiting	2024-05	UK, USA, India, China, Germany, France, Spain, Italy, Netherlands, Poland, Austria, Turkey, Canada, Brazil, Mexico, Japan, South Korea, Australia
A Study of Calderasib (MK-1084) in KRAS Mutant Advanced Solid Tumors (MK-1084-001) NCT05067283 · Advanced Solid Tumors Drugs: Adrucil, Calderasib, Carboplatin	Phase 1	Recruiting	2021-12	USA, China, Spain, Italy, Denmark, Poland, Switzerland, Turkey, Canada, Japan, South Korea, Taiwan, Australia, Israel
A Clinical Study of Ifinatamab Deruxtecan Based Treatment Combinations or as Monotherapy to Treat Metastatic Castrate Resistant Prostate Cancer (mCRPC) (MK-2400-01A/IDeate-Prostate02) NCT06863272 · Castration-Resistant Prostatic Cancer, Metastasis Drugs: Abiraterone, Docetaxel, Enzalutamide	Phase 1/2	Recruiting	2025-07	Ireland, UK, USA, Germany, France, Spain, Italy, Netherlands, Poland, Turkey, Canada, Brazil, South Korea, Taiwan, Australia, Israel
KEYMAKER-U04 Substudy 04D: A Clinical Study of New Treatments Given With Enfortumab Vedotin and Pembrolizumab in People With Urothelial Cancer (MK-3475-04D/KEYMAKER-U04) NCT07232602 · Bladder Cancer Drugs: Keytruda, MK-3120, Pembrolizumab	Phase 1/2	Recruiting	2026-02	UK, USA, France, Spain, Netherlands, South Korea, Israel
A Study to Assess Efficacy and Safety of Pembrolizumab With or Without Sacituzumab Tirumotecan (MK- 2870) in Adult Participants With Resectable Non Small Cell Lung Cancer (NSCLC) Not Achieving Pathological Complete Response (pCR) (MK-2870-019) NCT06312137 · Non Small Cell Lung Cancer Drugs: Carboplatin, Cisplatin, Gemcitabine	Phase 3	Recruiting	2024-04	UK, USA, China, Germany, France, Spain, Italy, Netherlands, Belgium, Poland, Switzerland, Austria, Czechia, Norway, Portugal, Turkey, Canada, Brazil, Mexico, Japan, South Korea, Taiwan, Australia, Israel
A Clinical Study of Belzutifan (MK-6482) and Zanzalintinib in People With Renal Cell Carcinoma (RCC) (LITESPARK-034/LS-034/MK-6482-034) NCT07489495 · Carcinoma, Renal Cell Drugs: Belzutifan, Zanzalintinib	Phase 3	Recruiting	2026-04	UK, USA, Germany, France, Spain, Italy, Netherlands, Denmark, Poland, Czechia, Turkey, Canada, Brazil, South Korea, Australia, Israel
A Clinical Study of Intismeran Autogene (V940) and Pembrolizumab (MK-3475) in People With Melanoma (V940-012/INTerpath-012) NCT06961006 · Malignant Melanoma Drugs: Intismeran autogene, Keytruda, Pembrolizumab	Phase 2	Recruiting	2025-05	USA, Germany, France, Spain, Italy, Poland, Portugal, Canada, Australia, Israel
A Study to Evaluate Zilovertamab Vedotin (MK-2140) Combination With Rituximab Plus Cyclophosphamide, Doxorubicin, and Prednisone (R-CHP) Versus Rituximab Plus Cyclophosphamide, Doxorubicin, Vincristine, and Prednisone (R-CHOP) in Participants With Previously Untreated DLBCL (MK-2140-010) NCT06717347 · Diffuse Large B-Cell Lymphoma Drugs: Adriamycin, Cyclophosphamide, Cytoxan	Phase 3	Recruiting	2025-01	USA, China, France, Spain, Italy, Netherlands, Belgium, Denmark, Poland, Switzerland, Portugal, Turkey, Canada, Brazil, Mexico, Japan, South Korea, Taiwan, Singapore, Australia, Israel
A Clinical Study of Calderasib (MK-1084) With Targeted Therapy and Chemotherapy in People With Colorectal Cancer (MK-1084-012/KANDLELIT-012) NCT06997497 · Colon Adenocarcinoma, Rectal Adenocarcinoma Drugs: Adrucil, Avastin, Bevacizumab	Phase 3	Recruiting	2025-07	UK, USA, China, Germany, France, Spain, Italy, Netherlands, Poland, Turkey, Canada, Brazil, Mexico, Japan, South Korea, Taiwan, Singapore, Australia, Israel
A Clinical Study of Sacituzumab Tirumotecan (Sac-TMT, MK-2870) in People With Breast Cancer (MK-2870-032) NCT06966700 · Breast Neoplasms, Triple Negative Breast Neoplasms, HR Low-Positive/HER2-Negative Breast Neoplasms Drugs: Adriamycin, Capecitabine, Carboplatin	Phase 3	Recruiting	2025-06	UK, USA, India, China, Germany, France, Spain, Italy, Belgium, Sweden, Poland, Czechia, Norway, Portugal, Turkey, Canada, Brazil, Japan, South Korea, Taiwan, Singapore, Australia, Israel
Substudy 06C: A Study of Investigational Agents With Pembrolizumab (MK-3475) and Chemotherapy in Participants With First-Line Locally Advanced Unresectable/Metastatic Gastroesophageal Adenocarcinoma (MK-3475-06C/KEYMAKER-U06) NCT06469944 · ClinicalTrials.gov ↗ · Gastroesophageal Junction, Gastroesophageal Adenocarcinoma, Esophageal Neoplasms Drugs: Adrucil, Capecitabine, Keytruda	Phase 1/2	Recruiting	2024-09	USA, China, Germany, France, Italy, Switzerland, Norway, Brazil, South Korea, Taiwan
Posaconazole (MK-5592) Intravenous and Oral in Children (<2 Years) With Invasive Fungal Infection (MK-5592-127) NCT04665037 · ClinicalTrials.gov ↗ · Invasive Fungal Infection Drug: Posaconazole	Phase 2	Recruiting	2022-02	USA, Belgium, Poland, Mexico, South Korea, Israel
A Study of Nemtabrutinib (MK-1026) Versus Comparator (Investigator's Choice of Ibrutinib or Acalabrutinib) in First Line (1L) Chronic Lymphocytic Leukemia (CLL)/ Small Lymphocytic Lymphoma (SLL) (MK-1026-011/BELLWAVE-011) NCT06136559 · Chronic Lymphocytic Leukemia, Small Lymphocytic Lymphoma Drugs: Acalabrutinib, Ibrutinib, Nemtabrutinib	Phase 3	Recruiting	2023-12	UK, USA, China, Germany, Spain, Belgium, Sweden, Denmark, Poland, Czechia, Norway, Portugal, Turkey, Canada, Brazil, Mexico, Japan, Taiwan, Australia, Israel
A Study of Ifinatamab Deruxtecan in Pediatric Participants With Relapsed or Refractory Solid Tumors (MK-9999-01D/LIGHTBEAM-U01) NCT07630974 · Malignant Neoplasm Drug: Ifinatamab Deruxtecan	Phase 1/2	Recruiting	2026-07	USA, France, Spain, Netherlands, Belgium, Sweden, Denmark, Czechia, South Korea, Australia, Israel
Belzutifan/MK-6482 for the Treatment of Advanced Pheochromocytoma/Paraganglioma (PPGL), Pancreatic Neuroendocrine Tumor (pNET), Von Hippel-Lindau (VHL) Disease-Associated Tumors, Advanced Gastrointestinal Stromal Tumor (wt GIST), or Solid Tumors With HIF-2α Related Genetic Alterations (MK-6482-015) NCT04924075 · Pheochromocytoma/Paraganglioma, Pancreatic Neuroendocrine Tumor, Von Hippel-Lindau Disease Drug: Belzutifan	Phase 2	Recruiting	2021-08	UK, USA, China, Germany, France, Spain, Italy, Netherlands, Sweden, Denmark, Norway, Portugal, Turkey, Canada, Japan, South Korea, Singapore, Australia, Israel
A Study of Belzutifan in Adolescent Participants With Solid Tumors (MK-9999-01E/LIGHTBEAM-U01) NCT07700758 · ClinicalTrials.gov ↗ · Malignant Neoplasm Drug: Belzutifan	Phase 2	Recruiting	2026-10	USA, France, Spain, Belgium, South Korea, Taiwan
Sacituzumab Tirumotecan (MK-2870) in Combination With Pembrolizumab Versus Pembrolizumab Alone in Metastatic Non-small Cell Lung Cancer (NSCLC) With Programmed Cell Death Ligand 1 (PD-L1) Tumor Proportion Score (TPS) ≥ 50% (MK-2870-007) NCT06170788 · Non-small Cell Lung Cancer (NSCLC) Drugs: Keytruda, Pembrolizumab, Sacituzumab tirumotecan	Phase 3	Recruiting	2023-12	UK, USA, China, Germany, France, Spain, Italy, Netherlands, Denmark, Poland, Czechia, Portugal, Turkey, Canada, Brazil, Mexico, Japan, South Korea, Taiwan, Australia
A Study of Pembrolizumab (MK-3475) in Pediatric Participants With an Advanced Solid Tumor or Lymphoma (MK-3475-051/KEYNOTE-051) NCT02332668 · Melanoma, Lymphoma, Solid Tumor Drug: Pembrolizumab	Phase 1/2	Recruiting	2015-03	UK, USA, Germany, France, Italy, Sweden, Portugal, Brazil, South Korea, Israel
Substudy 03C: A Study of Combination Therapies in Participants With Renal Cell Carcinoma With Recurrent Disease During or After Anti-PD-(L)1 Therapy (MK-3475-03C/KEYMAKER-U03) NCT07049926 · Renal Cell Carcinoma Drugs: Belzutifan, Zanzalintinib	Phase 1/2	Recruiting	2025-07	UK, USA, France, Spain, Poland, South Korea, Israel
Substudy 01I: A Study of Investigational Agents in Participants With Previously Treated Stage IV Squamous Non-small Cell Lung Cancer (NSCLC) (MK-3475-01I/KEYMAKER-U01I) NCT06780098 · ClinicalTrials.gov ↗ · Lung Neoplasm Drugs: Docetaxel, Ifinatamab Deruxtecan, R-DXd	Phase 2	Recruiting	2025-05	USA, China, Germany, Spain, Italy, Poland, Turkey, Israel
A Clinical Trial of Adjuvant Intismeran (V940) With or Without Pembrolizumab Coformulated With Berahyaluronidase Alfa (MK-3475A) in High-Risk Stage I Non-Small Cell Lung Cancer (V940-014) NCT07513376 · Non-small Cell Lung Cancer Drugs: Intismeran autogene, Pembrolizumab Formulated with Berahyaluronidase Alfa	Phase 3	Recruiting	2026-05	UK, USA, China, Germany, France, Spain, Italy, Netherlands, Poland, Turkey, Canada, Brazil, Japan, South Korea, Taiwan, Australia, Israel
A Clinical Trial of Ifinatamab Deruxtecan in People With Advanced Esophageal Cancer (MK-3475-06F) NCT07405151 · ClinicalTrials.gov ↗ · Oesophageal Squamous Cell Carcinoma Drug: Ifinatamab Deruxtecan	Phase 1/2	Recruiting	2026-03	USA, China, Switzerland, Czechia, Norway, Brazil, Japan, South Korea, Taiwan
KEYMAKER-U01 Substudy 01A: Efficacy and Safety Study of Pembrolizumab (MK-3475) With or Without Chemotherapy When Used With Investigational Agents in Treatment-naïve Participants With Stage IV Non-small Cell Lung Cancer (NSCLC) (MK-3475-01A/KEYMAKER-U01A) NCT04165070 · Carcinoma, Non-Small-Cell Lung Drugs: Abraxane, Carboplatin, Ifinatamab Deruxtecan	Phase 1/2	Recruiting	2019-12	USA, Spain, Italy, Poland, Canada, South Korea, Taiwan, Israel
A Clinical Study of Intismeran Autogene (V940) and BCG in People With Bladder Cancer (V940-011/INTerpath-011) NCT06833073 · Urinary Bladder Neoplasms, Non-Muscle Invasive Bladder Neoplasms, Carcinoma in Situ Drug: Intismeran autogene	Phase 2	Recruiting	2025-03	UK, USA, Germany, France, Spain, Italy, Netherlands, Denmark, Poland, Canada, Brazil, Australia
A Study to Evaluate Safety and Efficacy of Bomedemstat (MK-3543-017) NCT06351631 · Thrombocythemia, Essential, Primary Myelofibrosis, Myelofibrosis Drug: Bomedemstat	Phase 3	Recruiting	2024-05	UK, USA, Italy, Australia
A Clinical Study of Raludotatug Deruxtecan in People With Ovarian Cancer (MK-5909-003). NCT06843447 · Ovarian Cancer Recurrent Drugs: Avastin, Bevacizumab, Carboplatin	Phase 1/2	Recruiting	2025-04	UK, USA, Spain, Switzerland, Canada, South Korea, Taiwan, Australia, Israel
A Study of Sotatercept (MK-7962) in Japanese Children With Pulmonary Arterial Hypertension (PAH) (MK-7962-032) NCT07646860 · Pulmonary Arterial Hypertension Drug: Sotatercept	Phase 2	Recruiting	2026-09	Japan
A Clinical Trial of MK-1045 and Rituximab in People With Follicular Lymphoma (MK-1045-007) NCT07634471 · Follicular Lymphoma Drugs: Adriamycin, Bendamustine, Cyclophosphamide	Phase 2/3	Recruiting	2026-06	USA, China, Spain, Italy, Poland, Turkey, South Korea, Taiwan, Australia, Israel
Substudy 01A: Zilovertamab Vedotin in Pediatric and Young Adult Participants With Hematologic Malignancies or Solid Tumors (MK-9999-01A/LIGHTBEAM-U01) NCT06395103 · B-cell Acute Lymphoblastic Leukemia, Diffuse Large B-cell Lymphoma, Burkitt Lymphoma Drug: Zilovertamab vedotin	Phase 1/2	Recruiting	2024-08	UK, USA, Germany, France, Spain, Italy, Netherlands, Belgium, Sweden, Denmark, Czechia, Turkey, Canada, Brazil, South Korea, Taiwan, Australia, Israel
Substudy 06D: Combination Therapies in Second Line (2L) Gastroesophageal Adenocarcinoma (MK-3475-06D/Keymaker-U06) NCT06445972 · Gastroesophageal Junction, Gastroesophageal Adenocarcinoma, Esophageal Neoplasms Drugs: Paclitaxel, Patritumab deruxtecan, Ramucirumab	Phase 1/2	Recruiting	2024-08	USA, China, Germany, France, Italy, Switzerland, Norway, Brazil, South Korea, Taiwan
A Study of Raludotatug Deruxtecan With or Without Bevacizumab as First-Line Maintenance Treatment in Non-HRD-Positive Advanced Ovarian Cancer (MK-5909-006, (ENGOT-ov102/GOG-3141/ REJOICE-Ovarian 04) NCT07776691 · Ovarian Cancer, Ovarian Neoplasms, Peritoneal Cancer Drugs: Avastin, Bevacizumab, Mvasi	Phase 3	Recruiting	2026-09	UK, USA, South Korea, Taiwan, Israel
A Clinical Study of MK-1045 in People With Non-Hodgkin Lymphoma (MK-1045-008) NCT07519772 · Lymphoma, Non-Hodgkin, Lymphoma, Follicular, Lymphoma, Large B-Cell, Diffuse Drug: MK-1045	Phase 1/2	Recruiting	2026-05	UK, USA, China, Germany, France, Spain, Italy, Poland, Turkey, Canada, Brazil, South Korea, Australia, Israel
A Clinical Study of Calderasib (MK-1084) in People With Advanced Solid Tumors (MK-1084-014) NCT07209111 · Neoplasm Malignant Drugs: Calderasib, Cetuximab	Phase 2	Recruiting	2025-12	UK, USA, China, Germany, France, Spain, Italy, Sweden, Denmark, Poland, Norway, Turkey, Canada, Japan, South Korea, Australia, Israel
A Clinical Study of Enlicitide (MK-0616) in Adults With Hyperlipidemia in India (MK-0616-038) NCT07821944 · ClinicalTrials.gov ↗ · Hyperlipidemia, Hypercholesterolemia Drugs: Enlicitide, Enlicitide Decanoate	Phase 3	Recruiting	2026-10	India
A Clinical Trial of MK-1045 in People With B-cell Cancer (MK-1045-006) NCT07709000 · ClinicalTrials.gov ↗ · Chronic Lymphocytic Leukaemia, Small Lymphocytic Lymphoma, Hematologic Malignancies Drugs: Acetaminophen, Avtozma, Dexamethasone	Phase 2	Recruiting	2026-10	Israel
A Study of Sacituzumab Tirumotecan (Sac-TMT, MK-2870) as Monotherapy and in Combination With Pembrolizumab (MK-3475) in Participants With Triple-Negative Breast Cancer (MK-2870-011/TroFuse-011) NCT06841354 · Triple Negative Breast Neoplasms Drugs: Abraxane, Carboplatin, Gemcitabine	Phase 3	Recruiting	2025-03	UK, USA, China, Germany, France, Spain, Italy, Netherlands, Belgium, Denmark, Poland, Czechia, Turkey, Canada, Brazil, Mexico, Japan, South Korea, Taiwan, Australia, Israel
A Clinical Study of Islatravir and Ulonivirine for People With HIV-1 Who Have Not Been Treated Before (MK-8591B-062) NCT07266831 · Human Immunodeficiency Virus Type 1 (HIV-1) Infection Drug: B/F/TAF	Phase 2/3	Recruiting	2025-12	USA, France, Spain, Canada, Mexico
A Study of Zilovertamab Vedotin (MK-2140) in Combination With Standard of Care in Participants With Relapsed or Refractory Diffuse Large B-Cell Lymphoma (rrDLBCL) (MK-2140-003) NCT05139017 · DLBCL, Diffuse Large B-Cell Lymphoma Drugs: Bendamustine, G-Csf, Gemcitabine	Phase 2/3	Recruiting	2022-01	UK, USA, China, France, Italy, Denmark, Poland, Turkey, Canada, Brazil, Mexico, Japan, South Korea, Australia, Israel
Extension Study for Participants in Studies That Include Belzutifan (MK-6482-043/LITESPARK-043) NCT07405164 · Von Hippel-Lindau Disease, Malignant Neoplasms Drugs: Belzutifan, Cabozantinib, Lenvatinib	Phase 3	Recruiting	2026-03	UK, USA, France, Spain, Netherlands, Belgium, Denmark, Poland, Czechia, Canada, Brazil, Japan, South Korea, Taiwan, Australia, Israel
A Clinical Trial of MK-8748 Compared to Aflibercept in Participants With Diabetic Macular Edema (MK-8748-004) NCT07705555 · Diabetic Retinopathy, Macular Edema Drugs: Aflibercept, Eylea, Tiespectus	Phase 3	Recruiting	2026-08	UK, USA, Australia
MK-3475A±Calderasib (MK-1084) in Completely Resected Stage IIA-IIIB (N2) KRAS G12Cm NSCLC (MK-1084-013) NCT07431827 · Non-small Cell Lung Cancer Drugs: Calderasib, Pembrolizumab Formulated with Berahyaluronidase Alfa	Phase 3	Recruiting	2026-03	UK, China, France, Spain, Italy, Poland, Turkey, Canada, Brazil, Japan, South Korea, Taiwan, Australia
A Clinical Study of Tulisokibart (MK-7240) to Treat Radiographic Axial Spondyloarthritis (MK-7240-013) NCT07133633 · Radiographic Axial Spondyloarthritis Drug: Tulisokibart	Phase 2	Recruiting	2025-09	UK, USA, China, Germany, Netherlands, Poland, Turkey, Canada, Brazil, South Korea, Taiwan
A Clinical Study of Patritumab Deruxtecan to Treat Breast Cancer (MK-1022-016) NCT07060807 · Breast Neoplasms Drugs: Abraxane, Capecitabine, Nab-paclitaxel	Phase 3	Recruiting	2025-07	UK, USA, China, Germany, France, Spain, Italy, Poland, Turkey, Canada, Brazil, Mexico, Japan, South Korea, Taiwan, Australia, Israel
A Study of Patritumab Deruxtecan in Pediatric Participants With Relapsed or Refractory Solid Tumors (MK-9999-01C/LIGHTBEAM-U01) NCT06941272 · Malignant Neoplasm Drug: Patritumab deruxtecan	Phase 1/2	Recruiting	2025-05	UK, USA, Germany, France, Spain, Italy, Netherlands, Belgium, Sweden, Denmark, Czechia, Turkey, Canada, Brazil, South Korea, Taiwan, Australia, Israel
A Clinical Trial of MK-1045 in People With B-cell Acute Lymphoblastic Leukemia (MK-1045-005) NCT07570173 · ClinicalTrials.gov ↗ · B-cell Acute Lymphoblastic Leukemia Drugs: Acetaminophen, Avtozma, Blinatumomab	Phase 2/3	Recruiting	2026-05	France, Spain, Italy, Netherlands, Sweden, Denmark, Canada, Japan, Israel
A Clinical Study of Molnupiravir to Prevent Severe Illness From Coronavirus Disease 2019 (COVID-19) in People Who Are High Risk (MK-4482-023) NCT06667700 · Coronavirus Disease (COVID-19) Drug: Molnupiravir	Phase 3	Recruiting	2024-12	UK, USA, Germany, France, Spain, Italy, Netherlands, Poland, Brazil, Mexico, Japan, South Korea, Taiwan, Australia
Doravirine (DOR) in Human Immunodeficiency Virus (HIV)-Infected Children Aged 4 Weeks to <12 Years and <45 kg (MK-1439-066) NCT04375800 · Human Immunodeficiency Virus (HIV) Infection Drugs: 2 NRTIs, DOR/3TC/TDF, Doravirine	Phase 2	Recruiting	2021-02	USA, Mexico
A Clinical Trial of MK-2010 Alone and With Other Treatments in Participants With Advanced Solid Tumors (MK-2010-002) NCT07793942 · ClinicalTrials.gov ↗ · Malignant Neoplam, Advanced Solid Tumors Drugs: Adrucil, Belzutifan, Carboplatin	Phase 2	Recruiting	2026-10	USA, Switzerland, Canada
A Clinical Trial of Raludotatug Deruxtecan (R-DXd) With or Without Bevacizumab in Participants With Ovarian Cancer Who Have Progressed During Treatment With PARP-inhibitors Treatment on First Line Maintenance (MK-5909-008/ENGOT-ov107/GOG-3142 / REJOICE-Ovarian05) NCT07743164 · ClinicalTrials.gov ↗ · Ovarian Cancer, Peritoneal Cancer, Fallopian Tube Cancer Drugs: Avastin, Bevacizumab, Carboplatin	Phase 3	Recruiting	2026-10	USA, Taiwan, Israel
KEYMAKER-U01 Umbrella Master Study: Studies of Investigational Agents With Either Pembrolizumab (MK-3475) Alone or With Pembrolizumab PLUS Chemotherapy in Participants With Non-small Cell Lung Cancer (NSCLC) (MK-3475-U01/KEYMAKER-U01) NCT04165798 · Carcinoma, Non-Small-Cell Lung	Observational	Recruiting	2019-12	USA, Spain, Italy, Poland, Canada, South Korea, Taiwan, Israel
A Clinical Study of MK-1084 With Other Treatments for Non-small Cell Lung Cancer (MK-3475-01F) NCT07286149 · Lung Neoplasm Malignant Drugs: Calderasib, Cetuximab, Erbitux	Phase 1/2	Recruiting	2026-04	USA, China, Germany, Spain, Italy, Brazil, South Korea, Israel
KEYMAKER-U01 Substudy 01J: A Study of Pembrolizumab Plus MK-1084 in Participants With Non-Small Cell Lung Cancer (NSCLC) With Kirsten Rat Sarcoma Viral Oncogene Homolog (KRAS) G12C Mutations (MK-3475-01J/KEYMAKER-U01J) NCT07252739 · Malignant Neoplasm Drugs: Calderasib, Cetuximab, Keytruda	Phase 2	Recruiting	2025-12	USA, China, Spain, Italy, Netherlands, Turkey, South Korea
A Clinical Trial of V175 and V175A in Healthy Adults NCT07855510 · ClinicalTrials.gov ↗ · Lower Respiratory Tract Infection Drug: Control vaccine	Phase 1	Recruiting	2026-10	Australia
A Substudy of Investigational Agents in Programmed Cell Death-1/Ligand 1 (PD-1/L1) Refractory Locally Advanced or Metastatic Urothelial Carcinoma (mUC) (MK-3475-04A) NCT05562830 · Urothelial Carcinoma Drugs: Keytruda, MK-3120, Pembrolizumab	Phase 1/2	Recruiting	2022-11	UK, USA, Spain, Italy, Netherlands, Denmark, Canada, South Korea, Australia, Israel
A Clinical Trial of Calderasib (MK-1084) and Durvalumab in People With Non-Small Cell Lung Cancer (MK-1084-015/KANDLELIT-015) NCT07554339 · Non-small Cell Lung Cancer Drugs: Calderasib, Durvalumab	Phase 3	Recruiting	2026-06	UK, USA, China, Germany, France, Spain, Italy, Netherlands, Poland, Turkey, Brazil, Japan, South Korea, Taiwan, Australia

Showing the 100 most recently updated of 210 trials (recruiting first). The rest are in the country registers linked in each row.

Registers list studies that are recruiting, about to open, active but closed to enrolment, or enrolling by invitation. The UK and USA registers cover industry-sponsored studies only. Titles and statuses are copied from the registry as published.

Merck Sharp & Dohme in the EU trials register (CTIS)

10 trials

Authorised or ongoing trials in the EU Clinical Trials Information System with Merck Sharp & Dohme as sponsor. Some are the same study as a ClinicalTrials.gov record above; the two registries share no common ID. Trials with a site in Ireland are listed first.

Study	Phase	Status	Countries
A clinical trial of MK-4605 in healthy participants (MK-4605-002) 2026-527786-30-00 · CTIS ↗ · Nervous System Diseases	Phase 1	Authorised	Belgium
A clinical trial of MK-1568 in participants with prostate cancer (MK-1568-001) 2026-526983-19-00 · CTIS ↗ · Neoplasms	Phase 1	Authorised	Netherlands
A Phase 2, Open-label, Multicenter Study to Determine the Safety, Tolerability, and Efficacy of MK- 1045 in Participants with Hematologic Malignancies 2025-522242-49-00 · CTIS ↗ · Neoplasms Drugs: MK-1045, Tocilizumab	Phase 2	Ongoing	Spain, Italy
LIGHTBEAM-U01 Substudy 01E: A Phase 2 Substudy to Evaluate the Safety and Efficacy of Belzutifan in Participants With Solid Tumors 2025-524515-37-00 · CTIS ↗ · Neoplasms Drug: Belzutifan	Phase 2	Ongoing	Belgium, Spain, Denmark + 2 more
A Phase 3, Randomized, Placebo-Controlled Study of Adjuvant Intismeran Autogene Plus Subcutaneous Pembrolizumab and Berahyaluronidase Alfa (MK-3475A) or Intismeran Autogene Monotherapy Versus Placebo in Participants With Completely Resected High-Risk Stage I Non-Small Cell Lung Cancer (INTerpath-014) 2025-522643-18-00 · Neoplasms Drugs: Intismeran autogene, Pembrolizumab Formulated with Berahyaluronidase Alfa	Phase 3	Ongoing	Greece, Poland, Italy + 5 more
A Phase 3, Randomized, Double-blind, Placebo- and Active-Comparator-Controlled Study of MK-1084 Plus Durvalumab Versus Placebo Plus Durvalumab in Participants With Locally Advanced, Unresected KRAS G12C-Mutant Non-Small Cell Lung Cancer Without Disease Progression Following Definitive Platinum-Based Chemoradiotherapy (KANDLELIT-015) 2025-522038-29-00 · Neoplasms Drugs: Calderasib, Durvalumab	Phase 3	Ongoing	Italy, Netherlands, France + 4 more
LIGHTBEAM-U01 Substudy 01D: A Phase 1b/2 Substudy to Evaluate the Safety and Efficacy of Ifinatamab Deruxtecan in Pediatric Participants With Relapsed or Refractory Solid Tumors 2025-522339-32-00 · CTIS ↗ · Neoplasms Drug: Ifinatamab Deruxtecan	Phase 1	Ongoing	France, Spain, Sweden + 8 more
A Phase 2 Open-Label, Umbrella Platform Design Study of Investigational Agent(s) in Participants With 2L/3L Unresectable Locally Advanced or Metastatic Esophageal Cancer: KEYMAKER-U06 Substudy 06F 2026-525213-31-00 · CTIS ↗ · Neoplasms Drug: Ifinatamab Deruxtecan	Phase 2	Ongoing	Czechia, Germany, France + 1 more
Protocol Title: KEYMAKER-U01 Substudy 01F: A Phase 1b/2 Umbrella Study With Rolling Arms of Investigational Agents for Previously Treated of Participants With Advanced or Metastatic Nonsquamous Non-small Cell Lung Cancer (NSCLC) With KRAS G12C Mutations 2024-512248-47-00 · CTIS ↗ · Neoplasms Drugs: Calderasib, Cetuximab, Patritumab deruxtecan	Phase 1	Ongoing	Italy, Germany, Greece + 3 more
Phase 1/2 Study of Intravesical MK-3120 in BCG-Naïve or BCG-Exposed High-Risk Non-muscle Invasive Bladder Cancer 2025-520467-40-00 · CTIS ↗ · Neoplasms Drug: MK-3120	Phase 1	Ongoing	Belgium, Greece, Austria + 5 more

Drugs in Merck Sharp & Dohme trials

168 compounds

Drugs and biologicals named as interventions in these trials, with the number of this sponsor's trials that name each one. Placebos and generic comparators are excluded.

+ 128 more in the trial list above.

Conditions in Merck Sharp & Dohme trials

171 conditions

By trial register

Register	Trials	Recruiting
Clinical trials in USA	185	105
Clinical trials in Spain	132	71
Clinical trials in South Korea	120	69
Clinical trials in Italy	116	64
Clinical trials in UK	115	60
Clinical trials in Canada	114	58
Clinical trials in Israel	113	64
Clinical trials in France	111	59
Clinical trials in Australia	109	57
Clinical trials in Poland	104	54
Clinical trials in Japan	99	49
Clinical trials in Germany	98	51
Clinical trials in Turkey	91	49
Clinical trials in China	90	47
Clinical trials in Taiwan	89	53
Clinical trials in Brazil	81	50
Clinical trials in Netherlands	64	40
Clinical trials in Mexico	63	30
Clinical trials in Belgium	54	30
Clinical trials in Denmark	49	30
Clinical trials in Czechia	47	28
Clinical trials in Switzerland	43	22
Clinical trials in Sweden	40	22
Clinical trials in Ireland	35	18
Clinical trials in Singapore	32	20
Clinical trials in Norway	31	18
Clinical trials in Portugal	30	16
Clinical trials in Austria	27	15
Clinical trials in India	7	6
Clinical trials in Egypt	4	1
EU register (CTIS)	10	—

A trial with sites in more than one country appears in each of those registers; recruiting counts cover the trials listed on this page.

Other sponsors in Healthy

Sponsor	Trials
Boehringer Ingelheim	15
University of Electronic Science and Technology of China	10
University of Copenhagen	7
Centre Hospitalier Universitaire de Saint Etienne	6
Olly, PBC	5
Shenzhen Institutes of Advanced Technology ,Chinese Academy of Sciences	5
The Hospital for Sick Children	4
Université Catholique de Louvain	4
Mario Negri Institute for Pharmacological Research	3
Heidelberg University	2

Sponsors with the most current trials registered for this condition.

Questions about Merck Sharp & Dohme trials

How many clinical trials does Merck Sharp & Dohme sponsor?

Merck Sharp & Dohme is the lead sponsor of 210 current trials on ClinicalTrials.gov in our USA, Spain, South Korea, Italy, UK, Canada, Israel, France, Australia, Poland, Japan, Germany, Turkey, China, Taiwan, Brazil, Netherlands, Mexico, Belgium, Denmark, Czechia, Switzerland, Sweden, Ireland, Singapore, Norway, Portugal, Austria, India and Egypt registers, and 10 authorised or ongoing trials in the EU register (CTIS), as of the registry sync on 10 November 2026. Completed and withdrawn studies are not counted.

Are Merck Sharp & Dohme trials recruiting?

Yes. 117 of its 210 ClinicalTrials.gov trials are recruiting. Eligibility and site contacts are on each trial's record. Only the study team can confirm whether a patient is eligible.

Which drugs is Merck Sharp & Dohme testing?

Its current trials name 168 drugs and biologicals as interventions. The most frequent are Pembrolizumab (69), Keytruda (59), Paclitaxel (30), Sacituzumab tirumotecan (30) and Carboplatin (25). The number in brackets is how many of its trials name each drug.

Does Merck Sharp & Dohme have clinical trials in Ireland?

Yes. 35 trials in our Ireland register (ClinicalTrials.gov). Some may be the same study registered in both. See the Irish clinical trials register for sites and contacts.

Where does this information come from?

Every trial, status, phase and condition on this page is copied from public ClinicalTrials.gov and EU CTIS records by a daily sync, grouped by the sponsor name each registry records. It says nothing about the organisation beyond its registered trials, and it is not medical advice.

How this page is built

Everything on this page is copied from public registry records — it is not written from memory, and nothing here describes the organisation beyond its registered trials. Each trial links to its own record so you can check it yourself.

ClinicalTrials.gov (U.S. National Library of Medicine) ↗ Trial IDs, titles, lead sponsor, phase, overall status, start date, conditions and intervention names
EU Clinical Trials Information System (CTIS) ↗ EU trial numbers, titles, sponsor, phase, status, therapeutic area and member-state countries

This page is built automatically: a daily sync job reads the registry records behind our trial registers and groups every current trial by its lead sponsor name, ignoring legal-form suffixes such as Inc. or Ltd. A small, hand-checked list joins the same organisation's different registry names (for example its EU legal entity). There is no AI drafting and no per-sponsor editorial pass. The “last verified” date above is the timestamp of that sync, not a review date. Our general editorial approach is described in our editorial standards and corrections policy. The the registries data on this page was last retrieved on 10 Nov 2026. How every register is built: methodology · fixes we have made: corrections log.

Please verify before you rely on this. This page is general information for life-science and pharmaceutical professionals. It is not medical advice, and it has not been reviewed by a clinician — our editorial team holds life-science qualifications, not clinical ones. It is not exhaustive and may not reflect the most recent label change. Always check the official prescribing information (US Prescribing Information or EU SmPC) and speak to your doctor or pharmacist before acting on anything here. Drugs in the same class are not automatically interchangeable, and approvals, brand names and indications differ between the US, the EU/Ireland (EMA/HPRA) and other regions. Spotted an error? Tell us — we correct promptly and log it.